• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Anesth . Clinical profiles and outcome of patients with COVID-19 in a specialized hospital in Japan

tetano

Editor, Senior Moderator
J Anesth


. 2021 Mar 4.
doi: 10.1007/s00540-021-02912-0. Online ahead of print.
Clinical profiles and outcome of patients with COVID-19 in a specialized hospital in Japan


Yutaka Oda[SUP] 1 [/SUP], Satoshi Shiraishi[SUP] 2 [/SUP], Motoko Shimada[SUP] 3 [/SUP], Osamu Kurai[SUP] 4 [/SUP]



Affiliations

Abstract

Purpose: To characterize the clinical features and outcome of patients treated at a specialized hospital for coronavirus disease 2019 (COVID-19).
Methods: We retrospectively reviewed the symptoms on admission, treatment, and outcome of a total of 300 patients with mild (peripheral oxygen saturation (SpO[SUB]2[/SUB]) ≥ 96%), moderate I (93% < SpO[SUB]2[/SUB] < 96%), moderate II (SpO[SUB]2[/SUB] ≤ 93%) and severe (requiring admission to the ICU or mechanical ventilation) COVID-19.
Results: Median age was 53 (interquartile range [IQR] 33-72) years and 57% was male. The number of patients with mild, moderate I, II and severe condition was 85, 138, 61 and 16, respectively. Common presenting symptoms were cough (n = 71), loss of taste (42), loss of smell (39), fever ≥ 37.5 ?C (36). Dyspnea was observed only 21 cases; 57 reported no symptoms on admission. Favipiravir, ciclesonide, dexamethasone, and heparin were administered in 106, 168, 65, and 38 patients, respectively, but not remdesivir. The median duration of hospitalization was 10 (7-15) days. All patients with mild and moderate I severity were discharged. Among the 77 patients classified as moderate II or severe, 3 were transferred to tertiary hospitals for further treatment on the day of admission. The respiratory condition worsened in 21 patients; 18 required transfer to tertiary hospitals 3 (median) days after admission and 3 died.
Conclusion: Respiratory condition recovered in 92%; whereas it worsened in 7% and the mortality rate was 1%. The ratios of male patients, of patients with diabetes mellitus in those with the decreased respiratory condition, were significantly higher than recovered.

Keywords: COVID-19; Pandemic; Specialized hospital.
 
Back
Top Bottom